首页> 美国卫生研究院文献>Stem Cells and Cloning : Advances and Applications >Treatment of osteonecrosis of the femoral head by core decompression and implantation of fully functional ex vivo-expanded bone marrow-derived mesenchymal stem cells: a proof-of-concept study
【2h】

Treatment of osteonecrosis of the femoral head by core decompression and implantation of fully functional ex vivo-expanded bone marrow-derived mesenchymal stem cells: a proof-of-concept study

机译:通过核心减压和植入功能齐全的离体扩增的骨髓间充质干细胞植入治疗股骨头骨坏死:概念验证

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundBased on several attributes involved in bone formation, bone marrow-resident mesenchymal stem cells (MSCs) have been employed in the treatment of patients suffering from femoral head osteonecrosis. Due to the low content of MSCs in the bone marrow, ex vivo expansion procedures are utilized to increase the cell number. Customarily, before administration of the resulting expanded cell product MSCs to the patient, its cellular identity is usually evaluated according to a set of “minimal phenotypic” markers, which are not modified by ex vivo processing. However, MSC functional (“reparative”) markers, which are severely impaired along the ex vivo expansion routine, are usually not assessed.
机译:背景技术基于涉及骨形成的若干属性,骨髓驻留间充质干细胞(MSC)已用于治疗股骨头坏死的患者。由于骨髓中MSC的含量低,因此采用离体扩增程序来增加细胞数量。通常,在将所得的扩增的细胞产物MSCs施用于患者之前,通常根据一组“最小表型”标记来评估其细胞特性,所述标记不会通过离体加工而被修饰。但是,通常不评估在体外扩增过程中严重受损的MSC功能(“修复”)标记。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号